Equity Details
Price & Market Data
Price: $1.90
Daily Change: -$0.07 / 3.68%
Daily Range: $1.82 - $1.94
Market Cap: $171,843,024
Daily Volume: 14,901
Performance Metrics
1 Week: -15.74%
1 Month: 24.66%
3 Months: 7.06%
6 Months: -0.55%
1 Year: -15.04%
YTD: %
About Innate Pharma S.A. (IPHA)
Essential market overview for Innate Pharma S.A. (IPHA). Current price: 1.90, daily change: -$0.07 / 3.68%. Market cap: 171,843,024. All key performance metrics for a full analysis.
Company Details
Employees: 163
Sector: Health technology
Industry: Pharmaceuticals: major
Country: France
Details
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
